Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Institut Curie patents


Recent patent applications related to Institut Curie. Institut Curie is listed as an Agent/Assignee. Note: Institut Curie may have other listings under different names/spellings. We're not affiliated with Institut Curie, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Institut Curie-related inventors


Prediction of recurrence for bladder cancer by a protein signature in tissue samples

The present invention pertains to the field of cancer prediction. Specifically, it relates to a method for predicting the risk of recurrence of bladder cancer in a subject after treatment of bladder cancer comprising the steps of determining the amount of at least one biomarker selected from the biomarkers shown... Institut Curie

Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates

The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.... Institut Curie

Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors

The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.... Institut Curie

Skin whitening peptide agents

The present invention provides new peptides useful as skin whitening agents and their uses in cosmetic or therapeutic applications.... Institut Curie

Map3k8 as a marker for selecting a patient affected with an ovarian cancer for a treatment with a mek inhibitor

The present invention relates to the use of MAP3K8 protein to predict clinical outcome of a patient affected with a cancer, in particular ovarian cancer, or to select a patient for a treatment comprising one MEK inhibitor. The invention further relates to a method for monitoring a patient affected with... Institut Curie

Compounds for preventing, inhibiting, or treating cancer, aids and/or premature aging

R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.... Institut Curie

Quinoline derivatives for the treatment of inflammatory diseases

The present invention relates to a compound of formula (I) wherein: Formula (II) means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R″ does not exist when Q is O; R′ independently represent a hydrogen atom or... Institut Curie

A quinoline derivative for the treatment of inflammatory diseases and aids

The present invention relates to a compound of formula (1) in the form of a base or addition salt with an acid, particularly a pharmaceutically acceptable acid. It further relates to a pharmaceutical composition including the compound and at least one pharmaceutically acceptable excipient, to a process for preparing said... Institut Curie

Device for manipulation of packets in micro-containers, in particular in microchannels

A microfluidic device for performing physical, chemical or biological treatment to at least one packet without contamination.... Institut Curie

Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule

The invention relates to the regulated expression of a chimeric antigen receptor (CAR) within a lentiviral vector. The CAR comprises a hook-binding domain that interacts with a hook, preferably encoded by the same lentiviral vector, which prevents proper processing and release of the CAR to the cell membrane. The invention... Institut Curie

Use of mcoln-1 modulators to regulate cell migration

The present invention relates to the use of modulators of Mcoln-1 for modulating the cells migration, in particular the migration of dendritic cells and tumor cells, especially for antitumoral vaccination, autoimmune diseases treatment, and metastasis prevention.... Institut Curie

New derivatives of cephalosporin for treating cancer

The present invention relates to a new class of cephalosporin derivatives of formula (I), notably having CXCR4 receptor antagonist effect, useful as a therapeutic agent for treating cancer, in particular for treating breast cancer, lung cancer and uveal melanoma. The invention further relates to a pharmaceutical composition comprising a compound... Institut Curie

Compositions having means for targeting at least one antigen to dendritic cells

A composition that can be used as a vaccine containing means for targeting at least one antigen to dendritic cells and as adjuvants a granulocyte macrophage colony stimulating factor and a CpG oligodeoxynucleotide and/or a CpG-like oligodeoxynucleotide. This composition can used to treat cancers, infectious diseases caused by bacterial, viral,... Institut Curie

Methods for the diagnostic of an autoimmune disease

An in vitro method for determining whether a patient has, or is at risk of having or developing an autoimmune disease or for assessing the severity or predicting the outcome of an autoimmune disease, comprising a step of detecting or quantifying in a biological sample obtained from said patient an... Institut Curie

Pro-apoptotic ras and raf peptides

The invention relates to pro-apoptotic peptides, useful in cancer treatment, and to chimeric peptides comprising a cell penetrating peptide linked to a pro-apoptotic peptide, wherein the pro-apoptotic peptide binds Ras or Raf proteins.... Institut Curie

Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest

wherein B represents the B fragment of Shiga toxin or a functional equivalent thereof, and X represents one or more polypeptides of therapeutic significance. Compositions for therapeutic use comprising the polypeptide B-X are also included.... Institut Curie








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Institut Curie in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Institut Curie with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###